Biologics medical device firm NovaBone Products has obtained approval from the US Food and Drug Administration (FDA) for its MacroFORM MIS Delivery System, which has been developed for use in minimally invasive orthopedic procedures.

The firm has developed the system for surgeons for control and precise delivery of bone grafting material to surgical sites that are not easy to access.

The system enables surgeons to deliver bone marrow aspirate (BMA) to a graft housed in a closed and ready to use minimally invasive cannula.

NovaBone Products sales and marketing vice president Dennis McBride said: "The MacroFORM MIS Delivery System builds off the commercial success of the intuitively-designed collagen devices we have launched over the past several months.

The firm introduced six new collagen products developed using its regenerative medicine technology.

NovaBone Products president Art Wotiz said: "Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body."

The firm, which is involved in bioactive glass design and manufacturing, developed the first bioactive synthetic bone graft.